Market Place
Sourcing Support
The Biopharmaceutical Cartel And High Drug Prices
10 Apr 2019 //
FORBES
Japan`s PMDA reviews hep B risk link to hep C therapies
04 May 2016 //
FIERCE ASIA
FDA Calls for Head-to-Head Trials in Revised Draft Guidance on Hepatitis C
03 May 2016 //
RAPS
Gilead meds face little threat from hep C rivals Merck, BMS and AbbVie: analyst
31 Mar 2016 //
FIERCE PHARMA MARKETING
AbbVie Receives CHMP Positive Opinion for VIEKIRAX®+ EXVIERA®Without Ribavirin
26 Feb 2016 //
PR NEWSWIRE
FDA expands use of Gilead`s liver drug to rare subset of patients
17 Feb 2016 //
REUTERS
Risk of Serious Liver Injury associated with Hepatitis C Treatments
10 Nov 2015 //
HEALTH CANADA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.